Meeting
2020 ASCO Virtual Scientific Program
Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.
Authors
Victoria Atkinson
University of Queensland, Brisbane, Australia
Victoria Atkinson , Kathleen Batty , Georgina V. Long , Matteo S. Carlino , Geoffrey David Peters , Prachi Bhave , Maggie A. Moore , Wen Xu , Lauren Julia Brown , Melissa Arneil , Megan Lyle , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10049)
DOI
10.1200/JCO.2020.38.15_suppl.10049
Abstract #
10049
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2021 ASCO Annual Meeting
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
First Author: Caroline Robert